# US 2021/0079481 A1 · Diagnostic assay for cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079481 A1
- Document ID: US20210079481A1
- Status: Published application
- Kind: A1
- Application number: 17/022,248
- Filed: 2020-09-16
- Published: 2021-03-18
- Earliest claimed: 2019-09-16
- Assignees: Stitch Bio, LLC
- Applicants: Stitch Bio, LLC
- Inventors: Anthony P. Shuber
- Web page: https://patentgrep.com/patent/US20210079481A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention provides methods of detecting cancer in a subject. The methods of the invention entail monitoring accumulation of passenger fusions over time in a subject. An increase in the level of passenger fusions over time is indicative of the presence of cancer in the subject.

## Claims

### Claim 1

A method of detecting for cancer in a subject, the method comprising:
conducting a first assay to detect passenger fusions in DNA obtained from a sample obtained from a subject at a first point in time; and
conducting a second assay at a second point in time to determine persistence of said passenger fusions in a second sample obtained from said subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein said passenger fusions are detected by comparison of nucleic acid obtained in said sample to a reference germline sequence obtained from said subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein said fusions are quantified.

### Claim 4 (depends on 1)

The method of claim 1, wherein said second assay further comprises determining whether said second sample contains an increased amount of said passenger fusions.

### Claim 5 (depends on 4)

The method of claim 4, wherein said determining step comprises determining a rate of change of said passenger fusions.

### Claim 6 (depends on 1)

The method of claim 1, wherein said passenger fusions are identified by comparing said DNA to germline DNA from the subject.

### Claim 7 (depends on 6)

The method of claim 6, wherein said comparing comprises comparing a sequence of said DNA to said germline DNA.

### Claim 8 (depends on 1)

The method of claim 1, wherein said first assay comprises sequencing DNA obtained from said sample.

### Claim 9 (depends on 7)

The method of claim 7, further comprising enriching the second sample for identified passenger fusions.

### Claim 10 (depends on 9)

The method of claim 9, wherein the enriching step comprises introducing one or more Cas endonuclease/guide RNA complexes into the second sample wherein guide RNAs target the identified passenger fusion in a sequence-specific manner.

### Claim 11 (depends on 10)

The method of claim 10, further comprising introducing an exonuclease to digest nucleic acid to which said complexes are not bound.

### Claim 12 (depends on 1)

The method of claim 1, further comprising providing a diagnostic report.
